SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity In Vitro SMAP-2 reduces cell viability of pancreatic ductal adenocarcinoma (PDA) cell lines in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SMAP-2 significantly reduces abdominal aortic aneurysms (AAA) incidence and aortic dilation in pro-AAA apolipoprotein E- (ApoE-/-) mice. SMAP-2 (15 mg/kg; i.g.; daily; 6 days a week; for approximately 14 days) has anti-tumor activity in pancreatic cancer mice model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NSG mice, with PANC89 cells xenograftDosage: 15 mg/kg Administration: Oral gavage, daily, 6 days a week, for approximately 14 days Result: Decreased tumor growth and tumor weight. Form:Solid IC50& Target:PP2A